RE
REPCF.US RepliCel Life Sciences Inc
- Market cap
- USD 7.36K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is REPCF.US undervalued?
Graham numberThe Graham number of RepliCel Life Sciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
RepliCel Life Sciences Inc fundamental analysis
No fundamental analysis for RepliCel Life Sciences Inc yet.
RepliCel Life Sciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About RepliCel Life Sciences Inc
0913693 B.C. Ltd., a regenerative medicine company, develops autologous cell therapies for the treatment of functional cellular deficits. Its treatments use autologous cell therapy to treat chronic tendon injuries, androgenetic alopecia, and skin aging by restoring cellular function to rejuvenate aging or sun damaged skin, regrow hair, and repair tendons. The company's product candidates include RCH-01, a cell therapy for pattern baldness; RCS-01, a cell therapy for aging or…
Full company profileRepliCel Life Sciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
RepliCel Life Sciences Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 168K | 354K | 354K | 354K | 354K | 354K | 354K | 353K | 354K |
| Gross Profit | -5.78K | -4.16K | 121K | 354K | 354K | 354K | 354K | 352K | 354K | - | 354K |
| Operating Income | -4.29M | -5.99M | -2.70M | -2.88M | -1.33M | -2.30M | -1.39M | -1.39M | -360K | 238K | 267K |
| EBITDA | -4.30M | -5.96M | -2.69M | -2.88M | -1.58M | -4.07M | -736K | -1.39M | -359K | 238K | 267K |
| Net Income | -4.27M | -6.01M | -2.78M | -3.05M | -1.58M | -4.07M | -743K | -312K | -97.3K | -402K | -238K |
| EPS | -0.54 | -0.32 | -0.13 | -0.13 | -0.06 | -0.13 | -0.02 | -0.01 | 0.00 | -0.01 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 1.83M | 846K | 3.23M | 505K | 421K | 592K | 798K | 288K | 147K | 97.0K | 80.9K |
| Total Liabilities | 622K | 1.17M | 3.68M | 4.93M | 5.48M | 7.43M | 6.71M | 4.82M | 4.66M | 5.01M | 5.11M |
| Shareholders' Equity | 1.21M | -320K | -455K | -4.43M | -5.06M | -6.84M | -5.92M | -4.53M | -4.51M | -4.91M | -5.03M |
| Cash & Short-term Investments | 1.51M | 497K | 2.42M | 52.7K | 51.6K | 238K | 430K | 76.4K | 1.81K | 5.52K | 5.50K |
| Total Debt | - | - | - | - | 76.0K | 34.3K | 41.0K | 873K | 682K | 1.02M | 1.12M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -3.54M | -5.39M | -386K | -2.78M | -765K | -2.51M | -1.41M | -1.41M | -531K | -296K | -158K |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.12 | 8.36 |
| Free Cash Flow | -3.54M | -5.39M | -386K | -2.78M | -765K | -2.51M | -1.41M | -1.41M | -531K | -296K | -158K |
| Ratios | |||||||||||
| ROE | -354.0% | - | - | - | - | - | - | - | - | - | - |
| ROA | -233.6% | -710.9% | -86.3% | -603.0% | -375.4% | -688.2% | -93.1% | -108.4% | -66.1% | -414.0% | -294.6% |
| Net Profit Margin | - | - | -1,660.5% | -861.7% | -446.7% | -1,151.4% | -210.0% | -88.2% | -27.5% | -113.6% | -67.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
RepliCel Life Sciences Inc dividends
RepliCel Life Sciences Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Aug 10, 2016.
Who owns RepliCel Life Sciences Inc
- Insiders 42.81%
- Institutions 0.00%
- Public & others 57.19%
- Shares outstanding 73.6M
- Free float 72.7M
RepliCel Life Sciences Inc company profile
- Company name
- RepliCel Life Sciences Inc
- Ticker
- REPCF.US
- ISIN
- CA76027P4006
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Fiscal year end
- December
- Address
- 570 Granville Street, Vancouver, BC, Canada, V6C 3P1
- Phone
- 604 248 8730
- Website
- replicel.com
About RepliCel Life Sciences Inc
0913693 B.C. Ltd., a regenerative medicine company, develops autologous cell therapies for the treatment of functional cellular deficits. Its treatments use autologous cell therapy to treat chronic tendon injuries, androgenetic alopecia, and skin aging by restoring cellular function to rejuvenate aging or sun damaged skin, regrow hair, and repair tendons. The company's product candidates include RCH-01, a cell therapy for pattern baldness; RCS-01, a cell therapy for aging or sun damaged skin; and RCT-01, a cell therapy for tendon degeneration. It is also involved in the developing DermaPrecise, a dermal injection device. 0913693 B.C. Ltd. has a licensing and collaborative agreement with YOFOTO (China) Health Industry Co. Ltd. to develop and commercialize programs. The company was formerly known as RepliCel Life Sciences Inc. and changed its name to 0913693 B.C. Ltd. in March 2025. 0913693 B.C. Ltd. is based in Vancouver, Canada.
RepliCel Life Sciences Inc management
4- Mr. Andrew SchuttePresident, CEO & Director · born 1991
- Dr. Kevin John McElwee Ph.D.Co-Founder & Chief Scientific Officer · born 1970
- Mr. David Kwok CPAChief Financial Officer
- Mr. Ben AustringChief Operating Officer